Company
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. The company’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date.
163 stories · page 7 of 9
Orla Mining stock climbs on production results plus more daily small cap movers
More and less costly gold production boosted shares of Orla Mining Ltd Friday plus other big percentage movers on news from the small and micro cap space
Tiziana to focus near-term on developing intranasal drug to treat CNS-based autoimmune diseases
“We aim to become a leading company pioneering intranasal therapies for CNS-based diseases and have sufficient capital to fund our programs until the first quarter of 2024,” said interim CEO Gabriele Cerrone
Tiziana finishes enrolling first patient cohort for expanded access program evaluating Foralumab in advanced stage multiple sclerosis
“This is the first time that non-active SPMS patients may receive a higher, 100 mcg dosing of intranasal foralumab versus the 50-mcg dosing previously studied,” said Gabriele Cerrone, the interim CEO of Tiziana
Tiziana Life Sciences starts enrollment of first patient cohort in program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis patients
"In addition to this exciting news about starting this new treatment program in non-active SPMS, we are pleased to report that we are on track to conduct PET scans on our first two patients from our original study in the upcoming months," s
Tiziana Life Sciences plans to submit IND for phase 1 trial of intranasal foralumab in Alzheimer's disease patients by Q3 2023
"I am thrilled to see the company advancing foralumab into another promising central nervous system (CNS)-related therapeutic area with high unmet need," said Tiziana chairman and interim CEO Gabriele Cerrone
Tiziana Life Sciences presents intranasal foralumab at Preserving the Brain scientific conference in Italy
“Having the first patient to ever receive intranasal foralumab for secondary progressive multiple sclerosis interviewed at an esteemed cultural institution such as Fondazione Prada only further validates our passion and focus to advance thi
Archive
NA Proactive news snapshot: Auxico Resources, Gratomic, Forte Minerals, Appia Rare Earths & Uranium, Tiidal Gaming Group, Royal Helium, TraceSafe UPDATE...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Tiziana Life Sciences reports continued improvements in second patient with secondary progressive multiple sclerosis after intranasal foralumab treatment
"Coupled with our PET imaging data demonstrating inhibition of microglial activation, I am truly excited and encouraged by the clinical benefits shown so far for the first two expanded access patients receiving intranasal foralumab for SPMS
Tiziana Life Sciences says Brigham and Women's Hospital gets grant to explore use of intranasal anti-CD3 mAb in ALS
"This prestigious research grant will be used to further study the role of intranasal anti-CD3 mAb in dampening the microglial activation which amplifies ALS disease progression," said Howard L Weiner, chairman of Tiziana's scientific advis
Tiziana Life Sciences says study using nasal anti-CD3 (Foralumab) presented at the Alzheimer's Association International Conference
The study was presented virtually at the AAIC by Dr Howard L. Weiner, co-director of the Ann Romney Center for Neurologic Diseases at the Brigham and Women's Hospital and chairman of Tiziana's Scientific Advisory Board on Sunday, July 31, 2
Tiziana Life Sciences appoints Dr Matthew Davis as its chief medical officer and acting chief scientific officer, effective immediately
The company noted that Dr Davis has extensive experience in new drug application (NDA) and biologic license application (BLA), US Food & Drug Administration (FDA) approvals and device clearances